In vitro activity of a new carbapenem antibiotic, BO-2727, with potent antipseudomonal activity. 1993

S Nakagawa, and T Hashizume, and K Matsuda, and M Sanada, and O Okamoto, and H Fukatsu, and N Tanaka
Tsukuba Research Institute, Banyu Pharmaceutical Co., Ltd., Japan.

BO-2727, a new 1-beta-methyl-carbapenem, was active at concentrations of 6.25 micrograms/ml or less against gram-positive and gram-negative bacteria, including some imipenem- and/or meropenem-resistant (MICs, > or = 12.5 micrograms/ml) Pseudomonas aeruginosa strains, against which it proved generally fourfold more active than imipenem and meropenem. BO-2727's antipseudomonal activity and its broad spectrum merit further investigation for clinical use by itself, since it was stable in the presence of renal dehydropeptidase I.

UI MeSH Term Description Entries
D007668 Kidney Body organ that filters blood for the secretion of URINE and that regulates ion concentrations. Kidneys
D008826 Microbial Sensitivity Tests Any tests that demonstrate the relative efficacy of different chemotherapeutic agents against specific microorganisms (i.e., bacteria, fungi, viruses). Bacterial Sensitivity Tests,Drug Sensitivity Assay, Microbial,Minimum Inhibitory Concentration,Antibacterial Susceptibility Breakpoint Determination,Antibiogram,Antimicrobial Susceptibility Breakpoint Determination,Bacterial Sensitivity Test,Breakpoint Determination, Antibacterial Susceptibility,Breakpoint Determination, Antimicrobial Susceptibility,Fungal Drug Sensitivity Tests,Fungus Drug Sensitivity Tests,Sensitivity Test, Bacterial,Sensitivity Tests, Bacterial,Test, Bacterial Sensitivity,Tests, Bacterial Sensitivity,Viral Drug Sensitivity Tests,Virus Drug Sensitivity Tests,Antibiograms,Concentration, Minimum Inhibitory,Concentrations, Minimum Inhibitory,Inhibitory Concentration, Minimum,Inhibitory Concentrations, Minimum,Microbial Sensitivity Test,Minimum Inhibitory Concentrations,Sensitivity Test, Microbial,Sensitivity Tests, Microbial,Test, Microbial Sensitivity,Tests, Microbial Sensitivity
D011549 Pseudomonas A genus of gram-negative, aerobic, rod-shaped bacteria widely distributed in nature. Some species are pathogenic for humans, animals, and plants. Chryseomonas,Pseudomona,Flavimonas
D002442 Ceftazidime Semisynthetic, broad-spectrum antibacterial derived from CEPHALORIDINE and used especially for Pseudomonas and other gram-negative infections in debilitated patients. Ceftazidime Anhydrous,Ceftazidime Pentahydrate,Fortaz,Fortum,GR-20263,LY-139381,Pyridinium, 1-((7-(((2-amino-4-thiazolyl)((1-carboxy-1-methylethoxy)imino)acetyl)amino)-2-carboxy-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-en-3-yl)methyl)-, inner salt, pentahydrate, (6R-(6alpha,7beta(Z)))-,Tazidime,GR 20263,GR20263,LY 139381,LY139381
D004150 Dipeptidases EXOPEPTIDASES that specifically act on dipeptides. EC 3.4.13.
D004355 Drug Stability The chemical and physical integrity of a pharmaceutical product. Drug Shelf Life,Drugs Shelf Lives,Shelf Life, Drugs,Drug Stabilities,Drugs Shelf Life,Drugs Shelf Live,Life, Drugs Shelf,Shelf Life, Drug,Shelf Live, Drugs,Shelf Lives, Drugs
D006090 Gram-Negative Bacteria Bacteria which lose crystal violet stain but are stained pink when treated by Gram's method. Gram Negative Bacteria
D006094 Gram-Positive Bacteria Bacteria which retain the crystal violet stain when treated by Gram's method. Gram Positive Bacteria
D006868 Hydrolysis The process of cleaving a chemical compound by the addition of a molecule of water.
D000077731 Meropenem A thienamycin derivative antibacterial agent that is more stable to renal dehydropeptidase I than IMIPENEM, but does not need to be given with an enzyme inhibitor such as CILASTATIN. It is used in the treatment of bacterial infections, including infections in immunocompromised patients. 3-(5-Dimethylcarbamoylpyrrolidin-3-ylthio)-6-(1-hydroxyethyl)-4-methyl-7-oxo-1-azabicyclo(3.2.0)hept-2-ene-2-carboxylic acid,Merrem,Penem,Ronem,SM 7338,SM-7338,SM7338

Related Publications

S Nakagawa, and T Hashizume, and K Matsuda, and M Sanada, and O Okamoto, and H Fukatsu, and N Tanaka
August 1997, The Journal of antimicrobial chemotherapy,
S Nakagawa, and T Hashizume, and K Matsuda, and M Sanada, and O Okamoto, and H Fukatsu, and N Tanaka
March 1995, Antimicrobial agents and chemotherapy,
S Nakagawa, and T Hashizume, and K Matsuda, and M Sanada, and O Okamoto, and H Fukatsu, and N Tanaka
October 1995, Antimicrobial agents and chemotherapy,
S Nakagawa, and T Hashizume, and K Matsuda, and M Sanada, and O Okamoto, and H Fukatsu, and N Tanaka
February 1995, Antimicrobial agents and chemotherapy,
S Nakagawa, and T Hashizume, and K Matsuda, and M Sanada, and O Okamoto, and H Fukatsu, and N Tanaka
May 1995, Antimicrobial agents and chemotherapy,
S Nakagawa, and T Hashizume, and K Matsuda, and M Sanada, and O Okamoto, and H Fukatsu, and N Tanaka
January 1998, Chemotherapy,
S Nakagawa, and T Hashizume, and K Matsuda, and M Sanada, and O Okamoto, and H Fukatsu, and N Tanaka
July 1987, Antimicrobial agents and chemotherapy,
S Nakagawa, and T Hashizume, and K Matsuda, and M Sanada, and O Okamoto, and H Fukatsu, and N Tanaka
May 1988, Antimicrobial agents and chemotherapy,
S Nakagawa, and T Hashizume, and K Matsuda, and M Sanada, and O Okamoto, and H Fukatsu, and N Tanaka
June 1994, Journal of chromatography. B, Biomedical applications,
S Nakagawa, and T Hashizume, and K Matsuda, and M Sanada, and O Okamoto, and H Fukatsu, and N Tanaka
June 1986, The Journal of antimicrobial chemotherapy,
Copied contents to your clipboard!